Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.12 USD
+0.03 (1.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CLRB 2.12 +0.03(1.44%)
Will CLRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLRB
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
Other News for CLRB
Cellectar to Restate Previously Issued Financial Statements ? Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
Cellectar Biosciences Faces Nasdaq Compliance Issue
Cellectar Biosciences receives noncompliance notification, to restate financials
Cellectar receives delinquency notification letter from Nasdaq, co to restate financial statements
Strong Buy Recommendation for Cellectar Biosciences on Positive Phase 2b Results and Solid Financials